Anti-Human T-Lymphocyte Immunoglobulin, Rabbit
Acute Myeloid Leukemia With 11q23 Abnormalities
Explore 25 assets in Acute Myeloid Leukemia With 11q23 Abnormalities →Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
other_biological
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02727803CT.gov Personalized NK Cell Therapy in CBT | — | Recruiting | — | — | — |
NCT01168219CT.gov Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Myeloid Leukemia With 11q23 Abnormalities
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit (this asset) | M.D. Anderson Cancer Center | P2 | BB · 66 |
| Daunomycin | National Cancer Institute (NCI) | P3 | BBB |
| Etoposide | M.D. Anderson Cancer Center | P3 | BBB |
| Idarubicin | Bruno C. Medeiros | P2 | BBB |
| Cytarabine | Alice Mims | P3 | BBB |
| Cyclophosphamide | M.D. Anderson Cancer Center | P3 | BBB |
| Fludarabine | M.D. Anderson Cancer Center | P3 | BBB |
| Cyclosporin A | National Cancer Institute (NCI) | P3 | BBB |
| Nivestim | M.D. Anderson Cancer Center | P3 | BBB |
+42 more in the Acute Myeloid Leukemia With 11q23 Abnormalities cohort
Other indications for Anti-Human T-Lymphocyte Immunoglobulin, Rabbit
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Myelodysplastic/Myeloproliferative Neoplasm | — | P2/3 | BBB · 75 |
| Plasma Cell Myeloma | — | P4 | BBB · 72 |
| Myeloproliferative Neoplasm | — | P2/3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Anti-Human T-Lymphocyte Immunoglobulin, Rabbit in Acute Myeloid Leukemia With 11q23 Abnormalities. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/anti-human-t-lymphocyte-immunoglobulin-rabbit-acute-myeloid-leukemia-with-11q23-abnormalities
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →